SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (132)	12/14/2000 1:05:36 PM
From: Jim Oravetz	Read Replies (1) of 164

Synsorb Biotech Won't Pursue Further Devt Of Synsorb Pk Dow Jones Newswires CALGARY -- Synsorb Biotech Inc. (SYBB) won't pursue further development of its Synsorb Pk drug, which was designed to prevent serious complications associated with E. coli infections. In a news release, Synsorb said the decision follows extensive discussions with its corporate partners and clinical advisers, as well as an assessment of internal resources. The company said it plans to focus on the aggressive development of its lead product, Synsorb Cd, which it belives offers a "more significant" market opportunity. Synsorb Cd is a potential treatment for recurrent C. difficile Associated Diarrhea, a condition caused by antibiotic use. Company Web Site: synsorb.com Synsorb Biotech Inc. (SYBB) said third party support for additional development of Synsorb Pk wasn't available and the financial and other resource requirements of carrying out two pivotal Phase III programs simultaneously would place "unreasonable strain" on the company. Synsorb's Cd drug has been granted fast track designation by the U.S. Food and Drug Administration and is undergoing Phase III clinical trials. As reported, Synsorb had entered into the planning stage for a new Phase III clinical study of Synsorb Pk. It said "simultaneous development of two Phase III drugs is not a practical proposition for the company at this time. Focusing exclusively on Synsorb Cd is a prudent use of the resources available to us." Synsorb reported encouraging interim results in July for Synsorb Pk in a sub-group, but it has determined that the additional resources required to validate these results in a large pivotal study would be "extremely expensive" and could slow development of "the more important" Synsorb Cd product. The company said it plans to meet the milestone of filing a new drug application for Synsorb Cd in late 2002 or early 2003. Synsorb Biotech is a pharmaceutical company focused on developming carbohydrate-based therapies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next